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Abstract
Sox9 is a master regulatory gene involved in
developmental processes, stem cells mainte-
nance and tumorigenesis. This gene is
expressed in healthy skin but even in several
skin neoplasms, where its expression patterns
often resembles those of the developing hair
follicle. In this study, samples from eleven dif-
ferent types of canine skin neoplasms (squa-
mous papilloma, squamous cell carcinoma,
infundibular keratinizing acanthoma, inferior
tricholemmoma, isthmic tricholemmoma, tri-
choblastoma, trichoepithelioma, malignant tri-
choepithelioma, pilomatricoma, subungual
keratoacanthoma, subungual squamous cell
carcinoma) were immunohistochemically
stained and evaluated for Sox9 with the aim to
correlate tumor phenotype with molecular
characteristics that may help to better define
tumor development, contribute to its diagnosis
and clinical management. Keratoacanthoma
excluded, all the skin neoplasms examined
showed a variable positivity to Sox9, especially
in the basal layers, but with major intensity in
neoplasms developing from the bulge region of
the hair follicle, as trichoblastoma. According
to our results, Sox9 could be employed as a
stem cell marker to better assess the role of
stem cells in canine epidermal and follicular
tumors.
Introduction
The SRY sex determining region Y-box 9
(Sox9) is a transcription factor involved in
high mobility group box transcription factor
family, that plays a key role in directing tissue
and cell morphogenesis, survival, and develop-
ment.1 Sox9 mutations were identified in 1994
as responsible for campomelic dysplasia, a rare
skeletal dysplasia associated with XY sex
reversal.2 Sox9 has emerged as a key regulator
of various developmental processes;3 in the
skin, in particular, Sox9 is expressed in the
sebaceous gland, sweat gland, outer root
sheath of the hair follicles1,3 and in the hair
stem cells located in the bulge.3 The bulge rep-
resents a highly specialized hair follicle niche
that preserves the proliferative potential of
adult stem cell.4 The hair follicle, indeed, rep-
resents an important stem cell reservoir in the
skin, both for epithelial stem cells1,3 and for
mesenchimal stem cells.5 Besides to be essen-
tial for outer root sheath differentiation and
the formation of hair stem cell compartment
itself,6 Sox9 is expressed in epithelial stem
cells in adult hair follicle, that give rise to all
epithelial cells of the hair follicle, the seba-
ceous gland, and the interfollicular epidermis.7
According to recent studies indeed, adult stem
cells are involved in tissue homeostasis main-
tenance and in wound healing processes.4 In
mouse, Sox9 absence in early stem cells can
block hair follicle morphogenesis and epider-
mal wound repair.1,4
Sox9 is highly expressed in several skin dis-
eases as psoriasis or acne,1 and generally in
adnexal-related neoplasms,1,3,8 basal cell carci-
noma,3 squamous cell carcinoma1 and metasta-
tic melanoma.9 The role of Sox9 in skin tumori-
genesis, however, needs to be clarified yet.1
Among various specific human bulge markers
that are similarly overexpressed in canine
bulge cells, Sox9 is one of the most represent-
ed. Canine bulge stem cells, indeed, strongly
resemble distribution and biochemical fea-
tures of the human ones.10
The aim of this study was to investigate the
immunopositivity for Sox9 in different canine
epidermal and hair follicle neoplasms; differ-
ences in Sox9 expression would help to corre-
late tumor phenotype with molecular charac-
teristics thus allowing to better define tumor
development, contribute to its diagnosis and
clinical management.
Materials and MethodsCase selection
Different types of canine epithelial tumors
were retrieved from the files of the
Department of Veterinary Pathology, Hygiene
and Public Health of Milan. Samples of squa-
mous papilloma (n=5), squamous cell carci-
noma (n=6), infundibular keratinizing acan-
thoma (n=4), inferior tricholemmoma
(n=5), isthmic tricholemmoma (n=2), tri-
choblastoma (n=12), trichoepithelioma
(n=7), malignan trichoepithelioma (n=3),
pilomatricoma (n=2), subungual keratoacan-
thoma (n=1), subungual squamous cell car-
cinoma (n=4) were selected. Normal skin tis-
sue surrounding the tumor was also included
in the study. 
The diagnosis of each tumor was revised
according to the criteria of the World Health
Organization classification. 
Immunohistochemical staining
Four-micrometer thick sections from rou-
tinely formalin-fixed and paraffin-wax embed-
ded samples were prepared on poly-L-lysine–
coated glass slides for immunohistochemistry.
The sections were deparaffinized in xylene
and rehydrated through graded alcohols.
Endogenous peroxidase was blocked using 3%
hydrogen peroxide in distilled water for 5 min,
then, antigen retrieval for formalin-fixed sam-
ples was accomplished by microwave irradia-
tion in citrate buffer, pH 6.0, for 10 min.
Normal goat serum for 30 min was employed to
block sections. Sections were then incubated
for 18 h at 4°C with anti-Sox9 rabbit polyclonal
antibody (HPA001758; Sigma-Aldrich, St.
Louis, MO, USA) diluted 1:200. The antibody
recognizes a Sox9 specific peptide of 117
amino acids with 96% identity with Canis
familiaris. The sections were incubated for 30
min with 1:200 goat anti-rabbit biotin conju-
gate antibody (Vector Laboratories,
Burlingame, CA, USA; BA 1000) and subse-
quently stained for 30 min with streptavidin-
biotin peroxidase kit (Vectastain Elite ABC,
Vector Laboratories, PK-6100). Positive stain-
ing was visualized with 3.3- diaminobenzi-
dine-4 HCl (Vectastain, Vector Laboratories,
SK-4100) and nuclei were counterstained with
Mayer’s hematoxylin. Sox9 reactivity of follicu-
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lar outer root sheath present in normal cuta-
neous tissue of tumor sample was used as
internal positive control. Negative control sec-
tions were produced by omission of the pri-
mary antibody.Evaluation of immunohistochemical data
The immunohistochemically stained tissue
slides were examined using standard light
microscopy. The staining results were inde-
pendently scored by the authors as follows:
Sox9 protein expression was assessed by cate-
gorizing immunoreaction of each tumor cell
type into four groups according to the propor-
tion of positive cells: 0, no positive cells; 1,
from 1% to 25% positive cells; 2, from 25% to
50%; 3, from 50% to 75%; 4, from 75% to 100%.
The intensity of labeling was graded as: W,
weak positive staining; M, moderate positive
staining; I, intense positive staining, and
scored as follows: W=1, M=2, I=3. A global
score was conferred adding together the posi-
tive cells percentage score and the intensity of
immunolabeling score.
Results
Sox9 immunohistochemical results are
reported in Table 1. In every section a portion
of healthy skin next to the neoplasms was
always included, as Sox9 internal positive tis-
sue control (Figure 1A). Immunohisto chemical
examination resulted always positive. In nor-
mal skin, Sox9 positive reaction was restricted
to the bulge region and outer root sheath of the
hair follicles and to germinative cells of the
sebaceous glands. Well differentiated sebo-
cytes, sweat glands and epidermal cells were
mostly negative. Only in a few cases Sox9 pos-
itive epithelial cells were present in basal and
spinous layers of hyperplastic, reactive epider-
mis near and above the neoplastic tissue.Squamous papilloma
In 4 of 5 squamous papillomas the number
of Sox9 positive cells varied from 1-25% (1
case) to 25-50% (1 case), or 50-75% (2 cases)
showing moderate to intense immunolabeling,
staining especially basal and suprabasal cells.
Only in 1 case, the percentage of Sox9 positive
cells ranged from 1% to 25% and appeared
weakly positive.Squamous cell carcinoma
Sox9 was positive in all 6 squamous cell car-
cinomas (Figure 1B), with a variable number
of positive cells, extending from 1-25% (2
cases) to 25-50% (2 cases) or 50-75% (2
cases). The intensity of staining being intense
in 1 case, moderate in 2, weak in 3.
Immunolabeling involved especially basal cell
layer and spinous cells, even if in 3 cases its
distribution was very irregular.Infundibular keratinizing acanthoma
Sox9 showed a variable positivity: in all 4
cases, ranging from a rare and weak staining
(2 cases) to a diffuse and intense immunola-
beling (1 case).
Inferior tricholemmoma
Sox9 showed a variable positivity in all 5 tri-
cholemmoma cases. The number of positive
cells usually ranged from 25% to 50% (3
cases), with intensity of staining from weak to
intense. Two tumors were diffusely (50-100%
of positive cells) and strongly positive.
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Table 1. Sox9 immunohistochemical results.
Neoplasm                                      Case no.    Positive cells    Signal intensity   Global score
Squamous papilloma                                         1                          1                                  1                                2
                                                                               2                          3                                  2                                5
                                                                               3                          1                                  2                                3
                                                                               4                          2                                  2                                4
                                                                               5                          3                                  3                                6
Squamous cell carcinoma                                1                          1                                  1                                2
                                                                               2                          3                                  2                                5
                                                                               3                          3                                  3                                6
                                                                               4                          1                                  1                                2
                                                                               5                          2                                  2                                4
                                                                               6                          2                                  1                                3
Infundibular keratinizing acanthoma             1                          1                                  1                                2
                                                                               2                          2                                  2                                4
                                                                               3                          1                                  1                                2
                                                                               4                          4                                  3                                7
Inferior tricholemmoma                                  1                          3                                  3                                6
                                                                               2                          2                                  2                                4
                                                                               3                          2                                  1                                3
                                                                               4                          2                                  3                                6
                                                                               5                          4                                  3                                7
Isthmic tricholemmoma                                   1                          3                                  3                                6
                                                                               2                          3                                  3                                6
Trichoblastoma                                                   1                          4                                  3                                7
                                                                               2                          4                                  3                                7
                                                                               3                          4                                  3                                7
                                                                               4                          4                                  2                                6
                                                                               5                          4                                  3                                7
                                                                               6                          4                                  3                                7
                                                                               7                          3                                  3                                6
                                                                               8                          4                                  3                                7
                                                                               9                          3                                  3                                6
                                                                              10                         4                                  3                                7
                                                                              11                         4                                  1                                5
                                                                              12                         2                                  2                                4
Trichoepithelioma                                              1                          2                                  2                                4
                                                                               2                          4                                  3                                7
                                                                               3                          3                                  2                                5
                                                                               4                          3                                  3                                6
                                                                               5                          2                                  3                                5
                                                                               6                          1                                  2                                3
                                                                               7                          3                                  2                                5
Malignant trichoepithelioma                           1                          3                                  2                                5
                                                                               2                          3                                  2                                5
                                                                               3                          2                                  3                                5
Pilomatricoma                                                     1                          3                                  2                                5
                                                                               2                          2                                  3                                5
Subungual keratoacanthoma                           1                          0                                   /                                 0
Subungual squamous cell carcinoma           1                          2                                  2                                4
                                                                               2                          1                                  2                                3
                                                                               3                          1                                  1                                2
                                                                               4                          1                                  2                                3
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Isthmic tricholemmoma
In both isthmic tricholemmomas, positive
cells varied from 50% to 75% of neoplastic
cells. An intense immunolabeling was detected
and involved mainly peripheral basal cells.Trichoblastoma
All 12 trichoblastoma (Figure 1C) were Sox9
positive; 9 tumors were diffusely positive (75-
100% of neoplastic cells in 7 cases, 50-75% in 2
cases) with an intense staining, whereas in 1
case Sox9 showed diffuse (75-100% of cells) but
weak, immunolabeling. In 2 cases there was a
variable percentage of positive cells (from 25%
to 100%) with a moderate intensity of staining.Trichoepithelioma
Four of 7 trichoepitheliomas (Figure 1D)
showed a very wide percentage of positive cells,
ranging from 1-25% to 75%; Sox9 immunolabel-
ing was moderate. In 3 cases, 25-50% to 75-
100% of the tumor cells showed an intense
staining. Sox9 was detected mainly in peripher-
al basal cells and in suprabasal cells with spin-
ous differentiation. Only in 1 case a rare and
weak immunolabeling was observed.
Malignant trichoepithelioma
All 3 tumors expressed Sox9. The percentage
of positive cells varied from 25-50% (1 case) to
75-100% (2 cases). The intensity was usually
moderate (2 cases) or intense (1 case).
Peripheral basal cells and suprabasal cells were
mostly positive.Pilomatricoma
The 2 tumors expressed from 25% to 75% of
positive cells, with a moderate to intense Sox9
positivity (Figure 1E).
Subungual keratoacanthoma
Sox9 was negative in neoplastic keratoacan-
thoma cells. Internal control, represented by
normal skin hair follicles, was mildly positive.Subungual squamous cell carcinoma
The percentage of positive cells in subun-
gual squamous cell carcinomas (Figure 1F)
ranged from 1-25% (3 cases) to 25-50% (1
case) of positive cells. The intensity of
immunolabeling varied from weak (1 case) to
moderate (3 cases), especially in spinous
and basal layer. Immunolabeling decreased
or disappeared in most differentiated cells.
Discussion
Genes involved in developmental processes
or tissue homeostasis maintenance are often
overexpressed in tumorigenesis.3,11 Sox9 is
implicated in a wide range of human neo-
plasms, especially in organs where it plays a
role in their developmental stages and in stem
cells maintenance,3,11 but it has been found
even in other neoplasms, as fibrosarcomas,
where Sox9 is not known to be required during
normal physiology.11 As regards skin, Sox9 is
present in the outer root sheet of human hair
follicle and sebaceous gland, especially in
basal layers; Sox9 has been also detected in
basal layer of interfollicular epidermis, too.1 In
canine normal skin, Sox9 positive cell distribu-
tion was similar to that reported in humans.3,8
In a few cases scattered Sox9 positive epithe-
lial cells were detected also in upper hyperplas-
tic epidermis above the neoplastic tissue; sim-
ilar findings have been described in humans
by Vidal et al.3 and Shi et al.1 This gene, indeed,
is required for the specification of early bulge
cells and its progeny; moreover it is responsi-
ble of maintenance of stem cells characteris-
tics in the adult bulge niche, whose action is
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Figure 1. Sox9 immunohistochemistry. A) Hair follicle positive control: transverse sections with various positive nuclei. B) Squamous
cell carcinoma: intense, diffuse, irregular nuclear positivity in neoplastic cells with basal and spinous differentiation (asterisks); positive
cells are also detected in reactive fibrous stroma. C) Trichoblastoma: cords and spirals of neoplastic epithelial cells almost entirely pos-
itive for Sox9. D) Trichoepithelioma; abundant keratin (asterisk) surrounded by basal and suprabasal epithelial cells intensely positive
(arrows). E) Pilomatricoma: wall of a neoplastic cyst with positive cells mostly in superficial layers. F) Subungual squamous cell carci-
noma with scattered positive spinous cells. Scale bars: A,C,D) 75 μm; B,F,E) 150 µm.
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necessary in a wound environment.4
As previously described by some authors,4,8
various cutaneous neoplasms mirror some of
Sox9 embryological expression patterns, some-
times even reflecting its spatial distribution
within the various follicular subcompart -
ments.8 Sox9 was detected in all the adnexal
tumors tested, with the exception of subungual
keratoacanthoma, maybe due to its origin from
the nailbed epithelium.12 Subungual squamous
cell carcinomas resulted moderately positive.
As for subungual keratoacanthoma, the origin
from a highly differentiated epithelium could
explain the reduced Sox9 expression as well as
the loss of other stem cell markers.13 Sox9
expression in epidermal keratinocytes indeed,
is prominently detected in undifferentiated
rather than in differentiated keratinocytes.1
Sox9 was expressed at the highest levels in
neoplasms strictly related to embryonal hair
follicle, as trichoblastomas. Both in human and
veterinary medicine, trichoblastomas are con-
sidered to be neoplasms deriving from  hair
follicle stem cells;14 our findings therefore sup-
port this hypothesis and confirm the results of
other studies performed in dogs employing dif-
ferent stem cell markers.13,15,16 The intensity of
immunolabeling and number of Sox9 positive
cells may be related to the cycling and bulge-
harboring portion of the follicle, respectively
represented by the hair stem and the isthmus.8
Sox9 immunolabeling was observed in high
percentage of cells also in tricholemmomas
and trichoepitheliomas especially in peripher-
al basal cells and in less differentiated
suprabasal cells. Regarding trichoepithelioma,
the  heterogeneity in Sox9 staining may reflect
the origin of this neoplasm from the three dif-
ferent parts of the hair follicle.12,13 Malignant
trichoepitheliomas, in lesser extent, show the
same immunolabeling variability. 
Tricholemmo mas, both inferior and isthmic
type, showed a variable positivity especially in
basal and suprabasal layers, but no relevant
differences in immunohistochemical reactivity
were observed. There is no general agreement
about the origin of these neoplasms; they are
supposed to derive respectively from the infe-
rior segment of the outer root sheet or from
the isthmus segment of the outer root sheet;
experimental data are rather controversial.3,13
Squamous cell carcinomas, both epidermal
and subungual type, and squamous papillomas
expressed Sox9 with various degrees of posi-
tivity. Squamous cell carcinoma was irregular-
ly Sox9 positive in accordance with previous
studies where different markers for stem cells
were considered.1,17,18 Sox9 expression patterns
in pilomatricomas resemble those of the devel-
oping and the post-natal hair follicle.8 In the
current study, according with a previous work
by Krahl and Sellheyer,8 basaloid cells/bulb
germ cells were Sox9 negative, while a Sox9
positivity was observed in more differentiated
cells. These neoplasms, therefore, have to be
considered as trichoepitheliomas with a
prominent matrical component. 
In recent years many efforts have been
made to find a logical classification of adnexal
tumors according to a new molecular-morpho-
logical characterization, investigating neo-
plasm stem cell biology.17 Regarding canine
tumors, the association between hair follicle
and various stem cell markers, as CD34, CK15
and Nestin, has been investigated,13,15,16 each
with its own characteristics feature and target.
Sox9may be proposed as another reliable stem
cell marker for dermopathologists to better
assess the role of stem cells in canine epider-
mal and follicular tumors. 
References
1. Shi G, Sohn KC, Li Z et al. Expression and
functional role of Sox9 in human epider-
mal keratinocytes. PLoS One 2013;8:
e54355.
2. Akiyama H. Control of chondrogenesis by
the transcription factor Sox9. Mod
Rheumatol 2008;18:213-9. 
3. Vidal VPI, Ortonne N, Schedl A. Sox9
expression is a general marker of basal
cell carcinoma and adnexal-related neo-
plasms. J Cutan Pathol 2008;35:373-9.
4. Nowak JA, Polak L, Pasolli HA, Fuchs E.
Hair follicle stem cells are specified and
function in early skin morphogenesis. Cell
Stem Cell 2008;3:33-43.
5. Mercati F, Pascucci L, Ceccarelli P,
Dall’Aglio C, Pedini V, Gargiulo AM.
Expression of mesenchymal stem cell
marker CD90 on dermal sheath cells of the
anagen hair follicle in canine species. Eur
J Histochem 2009;53:159-66.
6. Vidal VP, Chaboissier MC, Lutzkendorf S,
Cotsarelis G, Mill P, Hui CC, et al. Sox9 is
essential for outer root sheath differentia-
tion and the formation of the hair stem cell
compartment. Curr Biol 2005;15:1340-51.
7. Christiano AM. Hair follicle epithelial stem
cells get their Sox on. Cell Stem Cell
2008;3:3-4.
8. Krahl D, Sellheyer K. Basal cell carcinoma
and pilomatrixoma mirror human follicu-
lar embryogenesis as reflected by their dif-
ferential expression patterns of Sox9 and
beta-catenin. Br J Dermatol 2010;162:
1294-301.
9. Rao P, Fuller GN and Prieto VG. Expression
of Sox9 in metastatic  melanoma - A poten-
tial diagnostic pitfall. Am J dermatopathol
2010;32:262-6.
10. Kobayashi T, Iwasaki T, Amagai M,
Ohyama M. Canine follicle stem cells can-
didates reside in the bulge and share char-
acteristic features with human bulge cells.
J Invest Dermatol 2010;130:1988-95. 
11. Matheu A, Collado M, Wise C, Manterola L,
Cekaite L, Tye AJ, et al. Oncogenicity of the
developmental transcription factor Sox9.
Cancer Res 2012;72:1301-15.
12. Goldschmidt MH, Dunstan RW, Stannard AA,
Von Tscharner C, Walder EJ, Yager JA.
Histological classification of epithelial and
melanocytic tumor of the skin of domestic
animals. In: World Health Organization
Classification of Tumors of Domestic
Animals. Second series, vol. 2, Washington
DC, USA: Armed Forces Institute of Pathology,
American Registry of Pathology; 1998. 
13. Brachelente C, Porcellato I, Sforna M,
Lepri E, Mechelli L, Bongiovanni L. The
contribution of stem cells to epidermal and
hair follicle tumors in the dog. Vet
Dermatol 2013;24:188-e41. 
14. Hurt MA, Kaddu S, Kutzner H, Cribier B,
Schulz T, Hartschuh W. Benign tumors
with follicular differentiation. In: World
Health Organization Classification of
Tumours, Pathology and Genetics of Skin
Tumours. Lyon: IARC press; 2006.
15. Pascucci L, Mercati F, Gargiulo AM, Pedini
V, Sorbolini S, Ceccarelli P. CD34 glycopro-
tein identifies putative stem cells located
in the isthmic region of canine hair folli-
cles. Vet Dermatol 2006;17:244-51.
16. Mercati F, Pascucci L, Gargiulo AM,
Dall’Aglio C, Ceccarelli P. Immunohi -
stochemical evaluation of intermediate fil-
ament nestin in dog hair follicles. Histol
Histopathol 2008;23:1035-41.
17. Sellheyer K. Stem cell markers can help
identify adnexal tumor differentiation
when evaluated in the context of morphol-
ogy: methodology matters. J Cutan Pathol
2011;38:460-74.
18. Bongiovanni L, Malatesta D, Brachelente
C, D’Egidio S, Della Salda L. β-catenin in
canine skin: immunohistochemical pat-
tern of expression in normal skin and
cutaneous epithelial tumours. J Comp
Pathol 2011;145:138-47.
                             Brief Report
EJH_2015_04-brief 229-238.qxp_Hrev_master  12/10/15  09:43  Pagina 232
No
n c
om
me
rci
al 
us
e o
nly
